156 related articles for article (PubMed ID: 37453413)
1. Cancer vaccines are back, revitalized.
Vonderheide RH
Med; 2023 Jul; 4(7):395-397. PubMed ID: 37453413
[TBL] [Abstract][Full Text] [Related]
2. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
[TBL] [Abstract][Full Text] [Related]
3. Materials engineering strategies for cancer vaccine adjuvant development.
Zhang X; Yang B; Ni Q; Chen X
Chem Soc Rev; 2023 May; 52(9):2886-2910. PubMed ID: 37014050
[TBL] [Abstract][Full Text] [Related]
4. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
5. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle delivery systems in cancer vaccines.
Krishnamachari Y; Geary SM; Lemke CD; Salem AK
Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
[TBL] [Abstract][Full Text] [Related]
7. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
[TBL] [Abstract][Full Text] [Related]
8. Outlining novel cellular adjuvant products for therapeutic vaccines against cancer.
Tefit JN; Serra V
Expert Rev Vaccines; 2011 Aug; 10(8):1207-20. PubMed ID: 21854313
[TBL] [Abstract][Full Text] [Related]
9. Roadmap to next-generation cancer vaccines.
Zheng Y; Zhong Z
J Control Release; 2022 Jul; 347():308-313. PubMed ID: 35561869
[TBL] [Abstract][Full Text] [Related]
10. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.
Cuzzubbo S; Mangsbo S; Nagarajan D; Habra K; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():615240. PubMed ID: 33679703
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy.
Lee K; Kim SY; Seo Y; Kim MH; Chang J; Lee H
Biomater Sci; 2020 Feb; 8(4):1101-1105. PubMed ID: 31793928
[TBL] [Abstract][Full Text] [Related]
12. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
[TBL] [Abstract][Full Text] [Related]
13. Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report.
Shao J; Liu Q; Shen J; Qian X; Yan J; Zhu Y; Qiu X; Lu C; Cen L; Tian M; Du J; Liu B
Front Immunol; 2022; 13():799026. PubMed ID: 35273594
[TBL] [Abstract][Full Text] [Related]
14. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
[TBL] [Abstract][Full Text] [Related]
15. Peptide vaccines in cancer-old concept revisited.
Kumai T; Kobayashi H; Harabuchi Y; Celis E
Curr Opin Immunol; 2017 Apr; 45():1-7. PubMed ID: 27940327
[TBL] [Abstract][Full Text] [Related]
16. Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land.
Yu G; He X; Li X; Wu Y
Biomed Pharmacother; 2022 Sep; 153():113464. PubMed ID: 36076493
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic vaccines for cancer: an overview of clinical trials.
Melero I; Gaudernack G; Gerritsen W; Huber C; Parmiani G; Scholl S; Thatcher N; Wagstaff J; Zielinski C; Faulkner I; Mellstedt H
Nat Rev Clin Oncol; 2014 Sep; 11(9):509-24. PubMed ID: 25001465
[TBL] [Abstract][Full Text] [Related]
18. Development of the PANVAC-VF vaccine for pancreatic cancer.
Petrulio CA; Kaufman HL
Expert Rev Vaccines; 2006 Feb; 5(1):9-19. PubMed ID: 16451103
[TBL] [Abstract][Full Text] [Related]
19. Melatonin as an adjuvant to therapeutic prostate cancer vaccines.
Connor TP
J Pineal Res; 2008 Sep; 45(2):224. PubMed ID: 18221313
[No Abstract] [Full Text] [Related]
20. Editorial: Approaches to Advance Cancer Vaccines to Clinical Utility.
Van Nuffel AMT; Boudousquié C; Tuyaerts S
Front Immunol; 2019; 10():2032. PubMed ID: 31507617
[No Abstract] [Full Text] [Related]
[Next] [New Search]
